Alithea Bio provides immunopeptidomics services, identifying and analyzing HLA-bound peptides to understand immune responses. Their HLA peptide cloud and machine learning tools enable precision immunotherapy development.
Funding
Funding not disclosed
Founders
Product
Problem
The development of effective immunotherapies is hindered by the complexity of identifying relevant HLA-presented peptides and predicting potential off-target effects, leading to challenges in target validation and safety assessment. Current methods often lack the sensitivity and throughput needed to comprehensively characterize the immunopeptidome and ensure the specificity of therapeutic interventions.
Solution
Alithea Bio offers comprehensive immunopeptidomics services and products that leverage high-sensitivity mass spectrometry, advanced bioinformatics, and machine learning to accelerate precision immunotherapy development. Their core offering, HLA-Compass, is a web-accessible database containing over 1.4 million unique HLA peptides, enabling researchers to identify true targets, assess off-target toxicity, and de-risk their immunotherapy pipelines. Alithea Bio's proteogenomics pipeline integrates genomic data analysis with proteomic technologies to identify and validate neoantigens from patient tumor samples. Additionally, they provide off-target quantification services using heavy-labeled reference peptides and PRM mass spectrometry to evaluate the safety risk of experimental drug candidates.
Target Audience
Alithea Bio serves immunotherapy developers, researchers, and pharmaceutical companies focused on developing safer and more effective T-cell therapies and personalized cancer treatments.
Features
- HLA-Compass: A database of HLA peptides derived from healthy organs, cancer cell lines, and tumor tissues.
- NeoZOOM: Mass spectrometry service for profiling HLA peptides directly from tumor or tissue samples.
- HLA Peptide Binding Predictions: AI-powered tools to predict peptide binding to HLA molecules.
- Off-Target Toxicity Prediction: Platform integrating healthy tissue data and machine learning to predict off-target peptide binding.
- Off-target quantification: Mass spectrometry-based quantification of validated off-target candidates on cells and tissues using heavy-labelled reference peptides.
- Proteogenomics pipeline: Integrates genomic data analysis with proteomic technologies for neoantigen discovery from patient tumor samples.
- sHLA based biomarkers: Development of blood-soluble HLA complexes (sHLA) based biomarkers for pre-clinical and clinical use.
- Standardized kits for sample preparation and peptide enrichment, tailored for HLA immunopeptidomics workflows.